

THE LANCET Infectious Diseases

Supplementary webappendix

This webappendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Stebbing J, Phelan A, I Griffin, et al. COVID-19: combining antiviral and anti-inflammatory treatments. *Lancet Infect Dis* 2020; published online Feb 27. [https://doi.org/10.1016/S1473-3099\(20\)30132-8](https://doi.org/10.1016/S1473-3099(20)30132-8).

Figure: Viral entry via clathrin-mediated endocytosis

The virus binds through its spike protein to ACE2 on the surface of AT2 epithelial cells (1), which induces activation of clathrin-mediated endocytosis. AAK1- and GAK-mediated phosphorylation of clathrin adapter proteins (2) starts the assembly of the clathrin cage around the enclosed virus, before it is pinched off and trafficked to endosomes (3). Inhibition of AAK1 and GAK by baricitinib thereby inhibits virus entry. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.

